Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novavax Inc (NASDAQ:NVAX)

7.17
Delayed Data
As of Jun 29
 +0.20 / +2.87%
Today’s Change
4.08
Today|||52-Week Range
15.01
-14.54%
Year-to-Date
Novavax (NVAX) Showing Signs Of A Dead Cat Bounce Today
Jun 28 / TheStreet.com - Paid Partner Content
The Brexit Vote Is Crushing These 3 Clinical-Stage Biotech Stocks
Jun 24 / MotleyFool.com - Paid Partner Content
Brexit Bargains: 3 Clinical-Stage Biotechs to Buy
Jun 24 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close6.97
Today’s open7.09
Day’s range6.90 - 7.25
Volume6,779,385
Average volume (3 months)5,715,230
Market cap$1.9B
Dividend yield--
Data as of 06/29/2016

Growth & Valuation

Earnings growth (last year)-62.16%
Earnings growth (this year)-60.19%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+18.24%
P/E ratioNM
Price/Sales60.70
Price/Book6.43

Competitors

 Today’s
change
Today’s
% change
OPHTOphthotech Corp+0.30+0.58%
RDUSRadius Health Inc+1.21+3.38%
BLUEbluebird bio Inc+2.51+6.33%
KITEKite Pharma Inc+0.11+0.22%
Data as of 06/29/2016

Financials

Next reporting dateAugust 3, 2016
EPS forecast (this quarter)-$0.25
Annual revenue (last year)$36.3M
Annual profit (last year)-$156.9M
Net profit margin-432.93%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Stanley C. Erck
Senior Vice President-
Quality Operations
Robert Darius
Corporate headquarters
Gaithersburg, Maryland

Forecasts

Partner Offers

Search for Jobs